Skip to main content
    • Aa
    • Aa
  • Print publication year: 2012
  • Online publication date: July 2012

Chapter 11 - Dissemination of clinical trial information: multiple audiences, multiple formats

The technological advances in molecular neuropharmacology and structural biology and the potential of large molecule therapeutics increase the number of potential drug targets and the ways in which these targets can be addressed to design novel therapeutic agents for CNS disorders. The target class approach has generated a large number of potential targets. Considerable progress has been made in exploiting an understanding of disease pathophysiology to identify novel targets for the treatment of neurodegenerative disorders. During the drug discovery process, target validation can be performed initially using in vitro or in vivo models but ultimately relies on demonstrating a clinical effect in patients. In Alzheimer's disease, two approaches to animal modeling are of interest: disease modification and cognition enhancement. An effective interface between basic research into disease mechanisms and the identification and validation of targets of interest to pre-clinical drug development is one of the key challenges.
Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Essential CNS Drug Development
  • Online ISBN: 9780511977640
  • Book DOI:
Please enter your name
Please enter a valid email address
Who would you like to send this to? *

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

L. Chipperfield , L. Citrome , J. Clark , et al. (2010). Authors' Submission Toolkit: a practical guide to getting your research published. Curr Med Res Opin, 26 (8), 1967–82.

L. Citrome (2008). Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand, 117 (6), 412–19.

L. Citrome (2009). Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf, 4 (3), 229–37.

L. Citrome (2010a). Citability of original research and reviews in journals and their sponsored supplements. PLoS One, 5 (3), e9876.

L. Citrome (2010b). Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract, 64 (6), 707–18.

L. Citrome (2010c). Relative vs. absolute measures of benefit and risk: what's the difference? Acta Psychiatr Scand, 121 (2), 94–102

L. Citrome , S. V. Moss , and C. Graf (2009). How to search and harvest the medical literature: let the citations come to you, and how to proceed when they do. Int J Clin Pract, 63 (11), 1565–70.

J. Clark , J. Gonzalez , B. Mansi , et al. (2010). Enhancing transparency and efficiency in reporting industry-sponsored clinical research: report from the Medical Publishing Insights and Practices initiative. Int J Clin Pract, 64 (8), 1028–33.

C. Graf , W. P. Battisti , D. Bridges , et al. (2009). International Society for Medical Publication Professionals. Research Methods & Reporting. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. Brit Med J, 339, b4330.

H. C. Kraemer and D. J. Kupfer (2006). Size of treatment effects and their importance to clinical research and practice. Biol Psychiat, 59 (11), 990–6.

S. Mathieu , I. Boutron , D. Moher , D. G. Altman , and P. Ravaud (2009). Comparison of registered and published primary outcomes in randomized controlled trials. J Am Med Assoc, 302 (9), 977–84.

K. F. Schulz , D. G. Altman , and D. Moher (2010). CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother, 1 (2), 100–7.

T. S. Stroup , J. P. McEvoy , M. S. Swartz , et al. (2003). The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bull, 29 (1), 15–31.